1例奥曲肽治疗舒尼替尼所致化疗性腹泻的药学监护

1例奥曲肽治疗舒尼替尼所致化疗性腹泻的药学监护

翟丹丹,刘建军,孔薇,梁海

合肥市第二人民医院亳州市人民医院,合肥市第二人民医院亳州市人民医院,合肥市第一人民医院,亳州市人民医院

收稿日期:2019-04-25 修回日期:2019-06-17 出版日期:2019-07-25

A Case of Pharmaceutical Care of Octreotide in the Treatment of Chemotherapeutic Diarrhea Caused by Sunitinib

ZHAI Dandan,Liu JianJun,KONG Wei and LIANG Hai

The Second Peoples Hospital of Hefei,The Second Peoples Hospital of Hefei,The First People′s Hospital of Hefe,Bozhou People′s Hospital

Received:2019-04-25 Revised:2019-06-17 Online:2019-07-25

摘要/Abstract

摘要： 目的：分享临床药师参与1例小肠间质瘤患者药物性腹泻治疗的临床药学实践经验与体会。方法：患者改用舒尼替尼化疗方案后出现腹泻，停药后腹泻好转，临床药师推断为舒尼替尼所致的药物性腹泻，在洛哌丁胺止泻失败的情况下，提出使用奥曲肽止泻，并对不良反应进行监护及用药宣教。结果：患者腹泻得到控制，未发生不良反应。结论：临床药师可通过药学监护有效降低药品不良反应，保障用药安全。

Abstract: Objective： To share the clinical pharmacy practice experience of the clinical pharmacist participating in treatment 1 case of drug-induced diarrhea of small intestinal stromal tumor patient. Methods： The diarrhea occurred after the patient switched to sunitinib chemotherapy， and improved after the withdrawal of the drug. The clinical pharmacist concluded that the diarrhea was caused by sunitinib. When loperamide failed to stop diarrhea， octreotide was proposed to stop diarrhea， and adverse reactions were monitored and medication education was conducted. Results： The diarrhea was under control and no adverse reaction occurred. Conclusion： Clinical pharmacists can effectively reduce adverse drug reactions and ensure drug safety by pharmaceutcal care.

翟丹丹,刘建军,孔薇,梁海. 1例奥曲肽治疗舒尼替尼所致化疗性腹泻的药学监护[J]. .

ZHAI Dandan,Liu JianJun,KONG Wei and LIANG Hai. A Case of Pharmaceutical Care of Octreotide in the Treatment of Chemotherapeutic Diarrhea Caused by Sunitinib[J]. .

参考文献

[1]Cherny N I.Evaluation and management of treatment -related diarrheain patients with advanced cancer: a review[J].J Pain Symptom Manage,2008,36 (4) : 413 -423．
[2]Richardson G,Dobish R．Chemotherapy induced diarrhea[J].J Oncol Pharm Pract, 2007,13 (4) : 181 -198．
[3]朱孝芹,叶敏.多靶点酪氨酸激酶抑制药舒尼替尼[J].中国新药与临床杂志,2007(06):474-478.
[4] 王之舟,闫素英,曾红,等。舒尼替尼治疗肾细胞癌致不良反应报告分析[J]。中国药房,2015,26(5)：644-647.
[5]FUSS M, STURTEWAGEN E, DE WAGTER C, et al. Dosimetric characterization of Gafchromic EBT film and its implication on film dosimetry quality assurance[J]. Phys Med Biol, 2007, 52(14): 4211-4225.
[6]Wai Lim,Hessamodini,Graves,Wong. Metastatic renal cell carcinoma: updateon epidemiology, genetics, and therapeutic modalities[J]. ImmunoTargets and Therapy,2013,2013(NULL).
[7] 毛立伟,等。奥曲肽对洛哌丁胺治疗失败的化疗性腹泻的临床疗效观察[J]。西南国防医药,2012,25(1)：25-27.
[8]俞娟,等。奥曲肽防治结直肠癌根治术后放疗致腹泻的效果[J]。中国医学物理学杂志,2017,34(4)：355-357.
[9]MOTZERRJ,RINIBI,BUKOWSKIRM,etal.Sunitinib in patients with metastatic renal cell carcinoma.[ J] .JAMA, 2006, 295 (21):2516-2524.
[10] MELMED S, POPOVIC V, BIDLINGMAIER M, et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial[J]. J Clin Endocrinol Metab, 2015, 100(4): 1699-1708.
[11] SHAHNT, KRISMG, PAOW, etal.Practical management of Patients with non-small-cell lung cancer treated with gefitinib [ J] .J Clin Oncol, 2005, 23(1):165 -174。
[12]ESCUDIERB, SZCZYLIKC, EISENT, etal.Randomized phaseIII trial of the Rafkinase and VEGFR inhibitor sorafenib(BAY43-9006)in patients with advance drenal cell cancer[ J] .JClinOncol(MeetingAbstracts), 2005, 23(16S):S380.
[13]MOTZERRJ, RINIBI, BUKOWSKIRM, etal.Sunitinib in patients with metastatic renal cell carcinoma[ J] .JAMA, 2006, 295 (21):2516-2524.
[14]Negrier S, Ravaud A (2007) Optimisation of sunitinib therapy in metastatic renal cell carcinoma: Adverse-event management. Eur J Cancer Suppl 5:12–19.
[15] Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R,Bjarnason G (2007) Sunitinib therapy for metastatic renal cell carcinoma:Recommendations for management of side eVects. CanUrol Assoc J 1:S41–S54.
[16]Desai JG, Pavlakis H, McAarthur N, et al. (2007) Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management.Asia-Pacific Journal of Clinical Oncology 3:167–176.
[17]Bhojani N, Jeldres C, Patard JJ, et al. (2008) Toxicities associated with the administration of sorafenib, sunitinib, and temsiroli-mus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53:917–930.
[18]毛丽伟,廖国清,王红梅,解国清,李仁德.奥曲肽对洛哌丁胺治疗失败的化疗性腹泻的临床疗效观察[J].西南国防医药,2012,22(01):25-26.
[19]梁平,王玉栋,侯娟,张蕾,郭艳楠,刘江.奥曲肽防治肿瘤放化疗相关性腹泻的系统评价[J].肿瘤,2015,35(12):1359-1367.
[20]张汝,阎翔,胡建,王晓香,肖兴荣,苏晓妹.醋酸奥曲肽治疗化疗相关性腹泻疗效观察[J].癌症进展,2009,7(06):654-656

快速检索引用检索图表检索高级检索